Literature DB >> 15480320

Dynamics of COX-2 in nasal mucosa and nasal polyps from aspirin-tolerant and aspirin-intolerant patients with asthma.

Laura Pujols1, Joaquim Mullol, Isam Alobid, Jordi Roca-Ferrer, Antoni Xaubet, César Picado.   

Abstract

BACKGROUND: Only dynamic studies can elucidate the discrepancies concerning the expression of the inducible COX-2 gene in inflammatory airway diseases.
OBJECTIVES: To quantify the expression and spontaneous regulation of COX-1 and COX-2 mRNAs in nasal polyps and nasal mucosa by real-time PCR.
METHODS: Nasal polyps were obtained from 16 aspirin-tolerant patients with asthma/rhinitis (ATAR) and 18 aspirin-intolerant patients with asthma/rhinitis (AIAR) undergoing nasal polypectomy. Nasal mucosa was obtained from 12 subjects undergoing nasal corrective surgery. All specimens were cut into 3 pieces. One was immediately snap-frozen in liquid nitrogen, and the remaining 2 were left at room temperature for 30 or 60 minutes before freezing. Data are presented as medians and 25th to 75th percentiles of 10 6 cDNA molecules/microg total RNA.
RESULTS: Baseline COX-2 mRNA levels were significantly lower in both ATAR (0.45; 0.13-1.20; P <.05) and AIAR (0.24; 0.12-0.41; P <.001) nasal polyps than in nasal mucosa (1.35; 0.52-3.90). COX-2 mRNA expression did not change over time in nasal mucosa but increased significantly in ATAR nasal polyps ( P <.05), reaching similar levels to nasal mucosa after 60 minutes. In contrast, COX-2 mRNA showed no significant change over time in AIAR nasal polyps. COX-1 mRNA was higher in nasal polyps than in nasal mucosa, and its expression was not modified over time in any group of patients.
CONCLUSION: These results suggest differential kinetics of COX-2 mRNA between nasal mucosa and nasal polyps. AIAR nasal polyps appear to have a greater abnormality of the COX-2 pathway than ATAR.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15480320     DOI: 10.1016/j.jaci.2004.07.050

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  11 in total

1.  Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)?

Authors:  Ludger Klimek; Ralph Dollner; Oliver Pfaar; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2014-06       Impact factor: 4.806

2.  Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis.

Authors:  J Roca-Ferrer; L Pujols; S Gartner; A Moreno; F Pumarola; J Mullol; N Cobos; C Picado
Journal:  Thorax       Date:  2006-03-03       Impact factor: 9.139

Review 3.  Mechanisms of aspirin sensitivity.

Authors:  César Picado
Journal:  Curr Allergy Asthma Rep       Date:  2006-05       Impact factor: 4.919

Review 4.  Pathogenesis of nasal polyps: an update.

Authors:  Rafal Pawliczak; Anna Lewandowska-Polak; Marek L Kowalski
Journal:  Curr Allergy Asthma Rep       Date:  2005-11       Impact factor: 4.919

Review 5.  Hypersensitivity to Aspirin and other NSAIDs: Diagnostic Approach in Patients with Chronic Rhinosinusitis.

Authors:  Joanna Makowska; Anna Lewandowska-Polak; Marek L Kowalski
Journal:  Curr Allergy Asthma Rep       Date:  2015-08       Impact factor: 4.806

6.  Release of cyclooxygenase-2 and lipoxin A4 from blood leukocytes in aspirin-exacerbated respiratory disease.

Authors:  Ajnacska Rozsasi; Akos Heinemann; Tilman Keck
Journal:  Allergy Rhinol (Providence)       Date:  2016-01-01

7.  Significance of susceptible gene expression profiles in nasal polyposis.

Authors:  De Yun Wang
Journal:  Clin Exp Otorhinolaryngol       Date:  2008-12-26       Impact factor: 3.372

8.  Activity of the cyclooxygenase 2-prostaglandin-E prostanoid receptor pathway in mice exposed to house dust mite aeroallergens, and impact of exogenous prostaglandin E2.

Authors:  Aida Herrerias; Rosa Torres; Mariona Serra; Alberto Marco; Laura Pujols; César Picado; Fernando de Mora
Journal:  J Inflamm (Lond)       Date:  2009-10-30       Impact factor: 4.981

9.  Signal transduction pathways (MAPKs, NF-κB, and C/EBP) regulating COX-2 expression in nasal fibroblasts from asthma patients with aspirin intolerance.

Authors:  Francesc Josep Garcia-Garcia; Joaquim Mullol; Maria Perez-Gonzalez; Laura Pujols; Isam Alobid; Jordi Roca-Ferrer; Cesar Picado
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

Review 10.  Cyclooxygenases and the pathogenesis of chronic rhinosinusitis and nasal polyposis.

Authors:  Josep M Guilemany; Jordi Roca-Ferrer; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2008-05       Impact factor: 4.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.